Stifel analyst Rick Wise raised the firm’s price target on Johnson & Johnson to $160 from $155 and keeps a Hold rating on the shares. Offsetting concerns about China and competitive pressures, Johnson & Johnson’s robust Innovative Medicine performance reiterated a still-positive second half of 2024 growth resiliency, the firm says. For MedTech specifically, despite China and competition pressuring Q2 MedTech performance, J&J’s earnings call comments left Stifel “feeling less concerned” than expected. Most notably, J&J seemed confident and optimistic about faster MedTech second half of the year growth. Net-net, for the MedTech company group outlook, the firm continues to use the phrase “steady-as-she-goes,” as Johnson & Johnson’s second half of 2024 utilization and procedure volume commentary seemed little changed overall.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Stock Market News Today, 7/17/24 – Indices Fall; Real Estate Data Beats Estimates
- JNJ Earnings: Johnson & Johnson’s Q2 Results Top Estimates
- Options Volatility and Implied Earnings Moves Today, July 17, 2024
- 3 Reasons Johnson & Johnson (NYSE:JNJ) Is an Attractive Dividend Growth Stock
- Johnson & Johnson (JNJ) Q2 Earnings Preview: Here’s What to Expect